CD133+Cell Selection Is an Alternative to CD34+Cell Selection for Ex Vivo Expansion of Hematopoietic Stem Cells

Abstract
CD133 is a new stem cell antigen that may provide an alternative to CD34 for the selection and expansion of hematopoietic cells for transplantation. This study compared the expansion capacities of CD133+ and CD34+ cells isolated from the same cord blood (CB) samples. After 14 days culture in stroma-free, serum-free medium in the presence of stem cell factor (SCF), Flt3-1, megakaryocyte growth and development factor (MGDF), and granulocyte colony-stimulating factor (G-CSF), the CD133+ and CD34+ fractions displayed comparable expansion of the myeloid compartment (CFC, LTC-IC, and E-LTC-IC). The expansion of CD133+ CB cells was up to 1262-fold for total cells, 99-fold for CD34+ cells, 109-fold for CD34+ CD133+ cells, 133-fold for CFU-GM, 14.5-fold for LTC-IC, and 7.5-fold for E-LTC-IC. Moreover, the expanded population was able to generate lymphoid B (CD19+), NK (CD56+), and T (CD4+ CD8+) cells in liquid or fetal thymic organ cultures, while expression of the homing antigen CXCR4 was similar on expanded and nonexpanded CD133+ or CD34+ cells. Thus, the CD133+ subset could be expanded in the same manner as the CD34+ subset and conserved its multilineage capacity, which would support the relevance of CD133 for clinical hematopoietic selection.

This publication has 28 references indexed in Scilit: